Talimogene laherparepvec (T-VEC) as cancer immunotherapy

F. J. Kohlhapp, A. Zloza, H. L. Kaufman

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was generated from an attenuated, recombinant herpes simplex virus. T-VEC has demonstrated therapeutic activity in melanoma patients and is being tested in a number of other cancers alone and in combination with standard cancer therapeutics and other immunotherapy agents. This review will discuss the current landscape of melanoma, the construction and application of T-VEC for melanoma along with other indications for T-VEC, as well as highlight some of the novel challenges with oncolytic virus immunotherapy as it enters into clinical practice.

Original languageEnglish (US)
Pages (from-to)549-558
Number of pages10
JournalDrugs of Today
Issue number9
StatePublished - Sep 2015
Externally publishedYes


  • Cancer immunotherapy
  • Melanoma
  • OncoVEX
  • Oncolytic virus
  • Talimogene laherparepvec

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Talimogene laherparepvec (T-VEC) as cancer immunotherapy'. Together they form a unique fingerprint.

Cite this